ArticleFrontiers in bioengineering and biotechnology2025
Metabolic engineering of
Article in Frontiers in bioengineering and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- ATP regeneration-driven biocatalytic production of 1,12-dodecanediol with improved cofactor supply.Bioresources and bioprocessing · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Medium- to long-chain α, ω-diols are valuable building blocks for polyesters and polyurethanes, yet their microbial synthesis from inexpensive alkane feedstocks remains largely undeveloped. The oleaginous yeast Yarrowia lipolytica offers advantages over bacterial systems such as Escherichia coli for alkane conversion due to its inherent capacity to metabolize hydrophobic substrates. Methods: To enable de novo α, ω-diol production from alkanes, we used CRISPR-Cas9 to delete ten genes involved in fatty alcohol oxidation (including FADH, ADH1 -8, and FAO1) and four genes linked to fatty aldehyde oxidation (FALDH1 -4). This generated the strain YALI17, with reduced over-oxidation activity. Further metabolic enhancement was achieved by overexpressing alkane hydroxylase genes, particularly ALK1. Fermentation performance was evaluated under controlled pH conditions using n-dodecane as the substrate. Results: The engineered strain YALI17 produced 1,12-dodecanediol at 0.72 mM from 50 mM n-dodecane -a 14-fold increase relative to the parental strain. ALK1 overexpression in YALI17 further raised production to 1.45 mM, and automated pH-controlled biotransformation achieved 3.2 mM. Discussion: This study demonstrates the first successful biotransformation of medium- to long-chain α, ω-diols directly from alkanes in yeast. The rational pathway design and oxidation-pathway blocking highlight Y. lipolytica as a promising cell factory for alkane-based biomanufacturing and lay the groundwork for sustainable production of high-value diol precursors through targeted metabolic engineering.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.